Phase 4
Completed N=30
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Dry Eye Disease · Keratoconjunctivitis Sicca
Source: ClinicalTrials.gov NCT05918406 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2025
Primary outcomePrimary: Number of Participants With Adverse Events — 30 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The objective of this study is to determine the safety of the nasal guide when utilized to aid in the administration of Tyrvaya (varenicline solution 0.03mg) Nasal Spray
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events |
30 | — |
Eligibility Criteria
Inclusion Criteria
- Be at least 18 years of age
- Have provided verbal and written informed consent
- Willing to comply with all study related visits and procedures
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT05918406). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.